Group 1 - The Hong Kong stock market saw a broad increase in early trading, with the healthcare sector performing actively, particularly the Hang Seng Healthcare Index ETF (159557) which rose by 3.56% with a turnover rate of 8.1% [1] - Among the constituent stocks, Innovent Biologics surged over 17%, while Zai Lab and China National Pharmaceutical Group both increased by more than 8% [1] - The 2025 American Society of Clinical Oncology (ASCO) annual meeting is highlighted as a significant event, showcasing the latest research from local companies such as Diagreat Pharmaceuticals, Kelun Pharmaceutical, and China National Pharmaceutical Group, with over 70 original research presentations from Chinese researchers [1] Group 2 - Donghai Securities noted that the recent presentation of numerous domestic innovative drug projects at the ASCO meeting indicates the growing international recognition of local innovative pharmaceutical companies, suggesting that innovative drugs are a key investment theme within the healthcare sector [1] - The report emphasizes investment opportunities in sub-sectors such as medical devices, traditional Chinese medicine, chain pharmacies, and medical services [1] - Changjiang Securities pointed out that domestic innovative drugs are currently undervalued, with some products showing potential to be the best in their class globally, supporting the outlook for these drugs to gain international market presence and valuation upside [2]
多家本土医药企业最新在研成果入选ASCO年会，恒生医疗指数ETF（159557）涨超3.5%，信达生物涨超17%，